Results 171 to 180 of about 7,770 (215)
Some of the next articles are maybe not open access.
Monitoring the Effect of Antifibrinolytic Agents and Thrombolytic Agents
Abstract Clinical conditions that may require the use of an antifibrinolytic agent (tranexamic acid or aminocaproic acid) to control fibrinolysis-associated bleeding are listed. Tests to monitor antifibrinolytic therapy are unavailable in most laboratories.Gene Gulati +2 more
exaly +2 more sources
Pharmacological agents: antifibrinolytics and desmopressin
Best Practice & Research Clinical Anaesthesiology, 2010This article provides an overview of the scientific evidence regarding the efficacy and safety of antifibrinolytic agents and desmopressin to reduce surgical blood loss. The synthetic derivatives of lysine are the only antifibrinolytics available in clinical practice since the withdrawal of aprotinin.
Yves, Ozier, Lorenn, Bellamy
openaire +2 more sources
Cimetidine—an Antifibrinolytic Agent?
Scandinavian Journal of Gastroenterology, 1983The mucosal fibrinolytic activity was estimated in 14 patients with duodenal ulcer before and after 4 weeks' treatment with cimetidine. A significant reduction in fibrinolytic activity in the corpus and antrum mucosa was found after treatment. In patients with healed ulcer after treatment, the activity was lower than in patients with unhealed ulcers ...
openaire +2 more sources
Antifibrinolytic agents in subarachnoid haemorrhage
Journal of Neurology, 1987For many years clinicians have used antifibrinolytic agents to try to reduce rebleeding after subarachnoid haemorrhage. Early studies of their effectiveness produced conflicting results. This paper re-evaluates the available trials and considers benefits in the light of potential complications.
openaire +2 more sources
Antifibrinolytic Agents in the Management of Traumatic Hyphema
Archives of Ophthalmology, 1983Clinical confusion often exists when therapeutic alternatives for a particular disease have not been rigorously compared. This problem is typical of the series of clinical decisions required in the management of traumatic hyphema and its complications. For example, should the patient (1) be admitted to the hospital, (2) undergo bilateral or unilateral ...
openaire +2 more sources
Human Placental Transfer of an Antifibrinolytic Agent (AMCA)
Acta Obstetricia et Gynecologica Scandinavica, 1970Abstract. A fibrinolytic inhibitor AMCA (trans p‐aminomethyl cyclohexane carboxylic acid) was given i.v. in a dose of 0.01 g/kg bodyweight to 12 mothers about to be delivered by Caesarean section. Immediately after delivery the concentration of AMCA was determined in the maternal blood and in cord blood.
S, Kullander, I M, Nilsson
openaire +2 more sources
Antifibrinolytic Agents and Desmopressin as Hemostatic Agents in Cardiac Surgery
The Annals of Pharmacotherapy, 2001OBJECTIVE: To review the use of systemic hemostatic medications for reducing bleeding and transfusion requirements with cardiac surgery. DATA SOURCES: Articles were obtained through computerized searches involving MEDLINE (from 1966 to September 2000).
openaire +2 more sources
A Direct Antifibrinolytic Agent in Major Orthopedic Surgery
Orthopedics, 2004abstract Aprotinin is a potent pharmacological agent that reduces bleeding. In current surgical practices, the rate of blood transfusions has decreased with the use of aprotinin. Recently, studies using aprotinin have been conducted in orthopedic surgery.
openaire +2 more sources
Fibrinolysis, Antifibrinolytic Agents, and Perioperative Considerations
2021Fibrinolysis is an integral component of hemostasis that acts to regulate fibrin formation. Its actions are counterbalanced by the coagulation process, maintaining against excess clot formation or hemorrhage. Excessive release of plasmin through surgery or other means can result in a pathophysiological state characterized by bleeding, inflammation, and
openaire +1 more source